N/A N=398 Mitigation of Major Hip Injury Due to Fall With a Smart Belt
Hip Injuries · Fractures, Hip · Fall Injury
Primary: Major Hip Injuries Due to Serious Hip-impacting Fall — 1.1; 12.1 percentage of participants — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=22 The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
Post Traumatic Stress Disorder
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 22 Participants
N/A N=27 ProAir Digihaler in COPD Disease Management: A Real World Study
COPD · COPD Exacerbation Acute
Primary: PIF Alerts and COPD Exacerbations — 2 Low PIF Alert
Phase 2 N=15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg
N/A N=19 Clinical Trial to Improve the Magnetic Levator Prosthesis
Blepharoptosis · Ptosis, Eyelid · Myasthenia Gravis
Primary: Change in Interpalpebral Fissure During Eye Opening — 4.5; 6.9; 6.2; 6.3 millimeters — p=>=0.46
Phase 4 N=66 Prophylactic Methylergonovine for Twin Cesarean
Twin; Complicating Pregnancy · Postpartum Hemorrhage
Primary: Change in Maternal Hemoglobin Level — 1.1; 2.1 g/dL
Phase 2 N=95 A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
Alzheimer Disease · Dementia · Brain Diseases
Primary: Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments — 0.8172; 0.8819; 0.8251; 0.8254 Intraclass correlation coefficient
Phase 4 N=447 Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations
Influenza · COVID-19
Primary: Percentage of Participants With HAI Seroconversion — 53.3; 52.6; 0.9; 33.5 percentage of participants — p=0.938
N/A N=595 Implementing Hypertension Screening Guidelines in Primary Care
Hypertension,Essential · White Coat Hypertension
Primary: Percentage of Patient Visits With Completion of Out-of-office BP Monitoring Within 6 Months of an Eligible Visit During the Pre-Implementation Period — 0.6; 5.4…
Phase 2 N=101 Dose-Finding Study of Intranasal Midazolam for Procedural Sedation in Children
Procedural Anxiety
Primary: Number of Children Who Achieved PSSS Score 2, 3, or 4 for 95% or Greater of the Scored Procedure — 9; 12; 20; 19 Participants
N/A N=23 AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals
Atrioventricular Block · Sick Sinus Syndrome · Symptomatic Bradycardia
Primary: Comparison of Change in Echocardiographic Parameters LV Dimension at End-diastole, LV Dimension at End-systole, and Tricuspid Annular Plane Systolic Excursion (cm) From…
N/A N=365 Validation of the Performance of the Electrocardiogram (ECG) Function in the Masimo INVSENSOR00057
Healthy · Atrial Fibrillation
Primary: Validation of the Performance of the Electrocardiogram (ECG) Function in the Masimo INVSENSOR00057 — 99.3; 100.0 percent
Phase 3 N=984 A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Diabetes Mellitus, Type 2
Primary: Change in Glycated Haemoglobin (HbA1c) — -1.55; -1.35 Percentage of HbA1c — p=<0.0001
Phase 1 N=38 A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Neoplasms
Primary: Maximum Tolerated Dose (MTD) Based on Number of Dose-limiting Toxicities (DLTs) — NA; NA μg (microgram)
Phase 1 N=25 Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
Degradation of Top2b and Top2a in Human by Dexrazoxane · Time Course and Degradation of Top2b in Human by Dexrazoxane · Effects of Dexrazoxane on Healthy Human
Primary: Participants With 95% Reduction in Topoisomerase 2 b From Baseline — 0; 0; 0; 0 Participants